Skip to main content

. 1990 Dec;62(6):1006–1007. doi: 10.1038/bjc.1990.427

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

N H Mulder ¹, P H Willemse ¹, H Schraffordt Koops ¹, E G de Vries ¹, D T Sleijfer ¹

PMCID: PMC1971582 PMID: 2257203

1006

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Creagan E. T., Ahmann D. L., Frytak S., Long H. J., Chang M. N., Itri L. M. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer. 1987 Feb 1;59(3 Suppl):638–646. doi: 10.1002/1097-0142(19870201)59:3+<638::aid-cncr2820591312>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
Khayat D., Lokiec F., Bizzari J. P., Weil M., Meeus L., Sellami M., Rouesse J., Banzet P., Jacquillat C. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res. 1987 Dec 15;47(24 Pt 1):6782–6785. [PubMed] [Google Scholar]
Mc Clay E. F., Mastrangelo M. J. Systemic chemotherapy for metastatic melanoma. Semin Oncol. 1988 Dec;15(6):569–577. [PubMed] [Google Scholar]
Mulder N. H., Sleijfer D. T., Smit J. M., De Vries E. G., Willemse P. H., Koops H. S. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma. Eur J Cancer Clin Oncol. 1986 Jul;22(7):879–881. doi: 10.1016/0277-5379(86)90377-9. [DOI] [PubMed] [Google Scholar]
Mulder N. H., Sleijfer D. T., de Vries E. G., Schraffordt Koops H., Samson M. J., Willemse P. H. Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol. 1989;115(1):93–95. doi: 10.1007/BF00391607. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES